Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) saw a 26% decline in attributable profit in the first nine months of 2025 to 256.2 million yuan from 344.1 million yuan in the year-ago period, a Friday filing with the Hong Kong bourse said.
Earnings per share fell to 0.37 yuan from 0.50 yuan previously.
Operating income jumped 0.4% to 6.76 billion yuan in the three quarters from 6.73 billion yuan a year prior.